Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze
Keywords: کورتیکواستروئید استنشاقی; AE; Adverse event; ANCOVA; Analysis of covariance; BIS; Budesonide inhalation suspension; FDA; Food and Drug Administration; ICS; Inhaled corticosteroid(s);